BRAF and melanoma: In the COLUMBUS trial, the median overall survival of patients with BRAF V600-mutant melanoma was 33.6 months with COMBO450 (encorafenib plus binimetinib), 23.5 months with ENCO300 (encorafenib), and 16.9 months with VEM (vemurafenib).